Menu
Menu
Menu
Menu
For companies that lack the resources for a direct presence in Switzerland and/or Europe, a partnership with EffRx offers the opportunity to exploit the potential of these markets. An early engagement, as well as a visceral understanding of the heterogeneity of the Swiss & European markets, are key to success. Partnering with EffRx Pharmaceuticals, offers various advantages to accelerate the launch of your medicines on the Swiss and /or European market.
EffRx is a Swiss-based commercial pharmaceutical company with capabilities and expertise in planning, and executing the commercialization of innovative medicines in Switzerland and Europe. EffRx affiliated presence in EU Big 4 countries and established partnerships beyond offers the opportunity to build on our know-how in launching products and on our first-hand product differentiation and turnaround expertise. EffRx dedicated and efficient infrastructure is designed to accelerate the go-to-market of niche medicines in Switzerland and Europe. EffRx offers customized, integrated, turnkey solutions that increases the overall value of your asset. Further, EffRx can offer hybrid licensing approaches which provide flexibility and valuable time gain towards a later greenfield or external out-licensing, hence providing flexibility to our partners to adapt towards most appropriate European operating model as data become available.
Our business strategy focuses on successfully shaping the late clinical development, approval, launch and valorization of medicines for niche and orphan diseases.
EffRx is actively seeking collaboration opportunities with small to mid-size biopharmaceutical companies that wishes to commercialize their medicines at late-stage development in Switzerland and/or Europe.
For our proprietary lead asset Binosto®, EffRx has established a global distribution model with reputable/distinguished companies who have extensive know-how and a strong local sales footprint.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® is further marketed in the US as well as in the Middle East and in Asian countries.
